imatinib mesylate has been researched along with Connective Tissue Neoplasms in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (81.25) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Blay, JY; Lebellec, L; Penel, N; Robin, YM | 1 |
| Ando, K; Kakeji, Y; Kojima, A; Maehara, Y; Morita, M; Oki, E; Saeki, H; Sugiyama, M; Taketomi, A; Tsujitani, S; Yamamoto, H; Yamashita, Y; Zhao, Y | 1 |
| Essodegui, F; Hermas, S; Hissane, EM; Mahdaoui, S; Noun, M; Oubaid, B; Samouh, N | 1 |
| Judson, I | 1 |
| Buchdunger, E; O'Reilly, T; Wood, J | 1 |
| Demetri, GD | 1 |
| Badawi, RD; Van den Abbeele, AD | 1 |
| Joensuu, H; Silberman, S | 1 |
| Dimitrijevic, S; Donato di Paola, E; Dumez, H; Judson, IR; Nielsen, OS; Sciot, R; Stroobants, S; Van Glabbeke, M; van Oosterom, AT; Verweij, J | 1 |
| Maturo, A; Peparini, N | 1 |
| Connolly, EM; Gaffney, E; Reynolds, JV | 1 |
| Hirohashi, K; Kanazawa, A; Kinoshita, H; Kubo, S; Shuto, T; Takemura, S; Tanaka, H; Yamamoto, S; Yamamoto, T | 1 |
| Dietrich, CG; Gartung, C; Geier, A; Maintz, C; Matern, S; Siewert, E; Tietze, L | 1 |
| Chang, KM; Huang, MJ; Lin, SC; Liu, CL; Tzen, CY | 1 |
| Huguier, M | 1 |
| Blanke, CD; Eisenberg, BL; Heinrich, MC | 1 |
8 review(s) available for imatinib mesylate and Connective Tissue Neoplasms
| Article | Year |
|---|---|
Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms, Connective Tissue; Sarcoma; Soft Tissue Neoplasms | 2020 |
Gastrointestinal stromal tumours (GIST): biology and treatment.
Topics: Benzamides; Biopsy, Needle; Clinical Trials as Topic; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Neoplasm Staging; Neoplasms, Connective Tissue; Piperazines; Prognosis; Pyrimidines; Risk Assessment; Stomach Neoplasms; Stromal Cells; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2002 |
Pharmacology of imatinib (STI571).
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Connective Tissue; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stromal Cells | 2002 |
Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Stromal Cells; Tomography, Emission-Computed | 2002 |
Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).
Topics: Antineoplastic Agents; Benzamides; Drug Monitoring; Enzyme Inhibitors; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasms, Connective Tissue; Piperazines; Pyrimidines; Radiopharmaceuticals; Stromal Cells; Tomography, Emission-Computed; Treatment Outcome | 2002 |
Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasms, Connective Tissue; Piperazines; Pyrimidines; Stromal Cells | 2002 |
Gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Neoplasms, Connective Tissue; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Stromal Cells | 2003 |
Gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Digestive System Surgical Procedures; Enzyme Inhibitors; Epidemiologic Methods; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunotherapy; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2001 |
1 trial(s) available for imatinib mesylate and Connective Tissue Neoplasms
| Article | Year |
|---|---|
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Connective Tissue; Piperazines; Pyrimidines; Sarcoma; Stromal Cells; Treatment Outcome | 2002 |
7 other study(ies) available for imatinib mesylate and Connective Tissue Neoplasms
| Article | Year |
|---|---|
Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: report of a case.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Neoplasms, Multiple Primary; Piperazines; Pyrimidines | 2011 |
[Pregnancy and extra-gastrointestinal stromal tumor: an exceptional association].
Topics: Abdominal Neoplasms; Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines | 2012 |
[Gastrointestinal stromal tumors: open problems].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Neoplasms, Connective Tissue; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Terminology as Topic | 2002 |
Treatment with STI571, a tyrosine kinase inhibitor, for gastrointestinal stromal tumor with peritoneal dissemination and multiple liver metastases.
Topics: Adult; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Neoplasm Invasiveness; Neoplasms, Connective Tissue; Peritoneum; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
[Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding].
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cardia; Chemotherapy, Adjuvant; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagectomy; Female; Gastrectomy; Gastric Mucosa; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Imatinib Mesylate; Incidental Findings; Male; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Piperazines; Polyps; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Shock, Hemorrhagic; Stomach Neoplasms; Stromal Cells; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Neo-adjuvant STI571 therapy for high-risk gastrointestinal stromal tumour.
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Neoplasms, Connective Tissue; Piperazines; Pyrimidines | 2004 |
[Effect of a tyrosine kinase inhibitors in a patient with a metastatic gastrointestinal stromal tumor].
Topics: Benzamides; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasms, Connective Tissue; Peritoneal Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stomach Neoplasms; Stromal Cells | 2001 |